IOVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Iovance Biotherapeutics Inc (IOVA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While hedge funds are showing increased interest, the technical indicators, financial performance, and lack of strong positive catalysts suggest a cautious approach. The stock's recent performance and analyst ratings do not indicate a compelling entry point for long-term gains.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 44.144, suggesting no clear trend. Moving averages are converging, showing indecision in price movement. Key support and resistance levels are at S1: 2.323 and R1: 2.72, with the pre-market price of $2.55 sitting near the pivot level of 2.522.
Hedge funds are significantly increasing their buying activity, with a 296.59% increase in the last quarter. Barclays analysts have raised the price target multiple times, indicating potential long-term upside.
The MACD and other technical indicators suggest bearish momentum. Financial performance shows declining EPS and gross margin, with negative net income.
In Q3 2025, revenue increased by 15.20% YoY to $67.45M. However, net income remains negative at -$91.25M, though it improved by 9.23% YoY. EPS dropped by -10.71% YoY to -0.25, and gross margin declined by 7.44% YoY to 29.61%.
Analysts are mixed. Barclays is optimistic with an Overweight rating and a price target increase to $10, while Goldman Sachs maintains a Sell rating with a price target of $2.
